Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17459703 | 1.00 | INMT (0.33) | INMTLMNAMAPTTSHRMEN1 | |
| SCHEMBL17459688 | 0.79 | BRD4 (0.35) | MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17459686 | 0.79 | BRD4 (0.35) | MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15392276 | 0.77 | LMNA (0.33) | INMTLMNAMAPTTSHRMEN1 | |
| SCHEMBL16582952 | 0.77 | LMNA (0.33) | INMTLMNAMAPTTSHRMEN1 | |
| SCHEMBL13848641 | 0.75 | BRD4 (0.43) | INMTLMNAMAPTMEN1KMT2A | |
| SCHEMBL17459694 | 0.75 | SMN1; SMN2 (0.38) | INMTLMNAMAPTTSHRMEN1 | |
| SCHEMBL16100768 | 0.72 | LMNA (0.43) | INMTLMNAMAPTTSHRMEN1 | |
| Lactic Acid SCHEMBL8056914 | 0.68 | LMNA (0.50) | LMNAMAPTTSHRMEN1KMT2A | |
| SCHEMBL6387239 | 0.68 | ALDH1A1 (0.41) | LMNAMAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758524-B2 | Compositions and methods for selectively depleting senescent cells | BIOVENTURES, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20180369223-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-12-27 | — | — | US | disclosed |
| US-10071087-B2 | Compositions and methods for selectively depleting senescent cells | BIOVENTURES, LLC (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170246155-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS | BIOVENTURES, LLC | 2017-08-31 | — | — | US | disclosed |
| EP-3177144-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS | Bioventures, LLC. (US) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016014625-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071087-B2 | Compositions and methods for selectively depleting senescent cells | CD47, MCL1, LIMS1 | INMT 3258/4885LMNA 58/4885MAPT 3398/4885 |
| US-10758524-B2 | Compositions and methods for selectively depleting senescent cells | CD47, MCL1, LIMS1 | INMT 3258/4885LMNA 58/4885MAPT 3398/4885 |
| US-20170246155-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS | CD47, MCL1, LIMS1 | INMT 3258/4885LMNA 58/4885MAPT 3398/4885 |
| US-20180369223-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS | CD47, MCL1, LIMS1 | INMT 3258/4885LMNA 58/4885MAPT 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.